Response to: 'Comment on Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results'.
Publication
, Journal Article
Homer, N; Grewal, DS; Mirza, RG; Lyon, AT; Gill, MK
Published in: Eye (Lond)
December 2015
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Eye (Lond)
DOI
EISSN
1476-5454
Publication Date
December 2015
Volume
29
Issue
12
Start / End Page
1630 / 1631
Location
England
Related Subject Headings
- Wet Macular Degeneration
- Recombinant Fusion Proteins
- Receptors, Vascular Endothelial Growth Factor
- Ophthalmology & Optometry
- Neovascularization, Pathologic
- Male
- Humans
- Female
- Angiogenesis Inhibitors
- 3212 Ophthalmology and optometry
Citation
APA
Chicago
ICMJE
MLA
NLM
Homer, N., Grewal, D. S., Mirza, R. G., Lyon, A. T., & Gill, M. K. (2015). Response to: 'Comment on Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results'. Eye (Lond), 29(12), 1630–1631. https://doi.org/10.1038/eye.2015.191
Homer, N., D. S. Grewal, R. G. Mirza, A. T. Lyon, and M. K. Gill. “Response to: 'Comment on Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results'.” Eye (Lond) 29, no. 12 (December 2015): 1630–31. https://doi.org/10.1038/eye.2015.191.
Homer N, Grewal DS, Mirza RG, Lyon AT, Gill MK. Response to: 'Comment on Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results'. Eye (Lond). 2015 Dec;29(12):1630–1.
Homer, N., et al. “Response to: 'Comment on Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results'.” Eye (Lond), vol. 29, no. 12, Dec. 2015, pp. 1630–31. Pubmed, doi:10.1038/eye.2015.191.
Homer N, Grewal DS, Mirza RG, Lyon AT, Gill MK. Response to: 'Comment on Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results'. Eye (Lond). 2015 Dec;29(12):1630–1631.
Published In
Eye (Lond)
DOI
EISSN
1476-5454
Publication Date
December 2015
Volume
29
Issue
12
Start / End Page
1630 / 1631
Location
England
Related Subject Headings
- Wet Macular Degeneration
- Recombinant Fusion Proteins
- Receptors, Vascular Endothelial Growth Factor
- Ophthalmology & Optometry
- Neovascularization, Pathologic
- Male
- Humans
- Female
- Angiogenesis Inhibitors
- 3212 Ophthalmology and optometry